RxDoctor Payments Data

Mike Rodriguez, MD

Cardiovascular Disease · Corpus Christi, TXNPI 1306847504

Payments from drug & device makers

$5,002in general payments, 2019–2025

Across 121 payments — averaging $41.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$2K
  • Medtronic$1K
  • Abiomed$671
  • Abbott$245
  • Johnson & Johnson$232
  • Merck$196
  • plus $570 from 12 others

What the payments were for

  • Travel & lodging$2,36047%
  • Food & beverage$2,64153%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,002 in reported general payments places this provider in the 55th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$142,888
Medicare patients
925
Services billed
2,061

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban475$371,504
XareltoRivaroxaban148$126,955
MultaqDronedarone Hcl79$83,619
Repatha SureclickEvolocumab57$36,911
EntrestoSacubitril/Valsartan28$22,375
BrilintaTicagrelor20$15,448
Atorvastatin Calcium793$6,938
Praluent PenAlirocumab11$5,247
Ranolazine ErRanolazine22$2,521
Carvedilol359$2,268
Dabigatran EtexilateDabigatran Etexilate Mesylate11$2,207
Rosuvastatin Calcium152$1,988
Metoprolol Succinate194$1,949
Amiodarone Hcl59$1,784
ClopidogrelClopidogrel Bisulfate247$1,714

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$79$371,504475 claims
Johnson & JohnsonXarelto$232$126,955148 claims
Sanofi-aventis U.S. LLCMultaq$47$83,61979 claims
NovartisEntresto$187$22,37528 claims
AstraZenecaBrilinta$65$15,44820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →